Skip to main
  1. Stocks
  2. Braveheart Bio Inc.
  3. Forecast
BRVE

BRVE Stock Forecast & Price Target

BRVE Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Braveheart Bio is viewed positively because BHB-1893 targets a clinically validated cardiac myosin inhibition mechanism with differentiated PK/PD, including faster steady state, lower accumulation, fewer DDI liabilities, and a potentially wider therapeutic window that could simplify dosing. In oHCM, that could translate into comparable efficacy with fewer titration steps, echoes, and monitoring burdens, while in nHCM the phase 2 data were especially encouraging with about a 5.5-6 point placebo-adjusted KCCQ benefit, ~0.5 mL/kg/min pVO₂ improvement, and early remodeling signals. With the IPO raising about $440M and funding both global phase 3 programs through completion into ~2029, the company has a de-risked runway to key readouts in 4Q26, 1H27, 2H27, and beyond.

Bears say

Braveheart Bio is a clinical-stage company with no product revenue and likely needs additional capital, creating clear financing risk before BHB-1893 can ever generate value. Its lead asset has only shown encouraging KCCQ and remodeling signals in a relatively small 12-week phase 2 study, while the global NOBLEHEART-HCM phase 3 trial still must prove those results at scale and across a broader population. The bearish view is further reinforced by competition and regulatory uncertainty: approved myosin inhibitors already have REMS programs, EDG-7500 could alter the convenience landscape, and comparable efficacy in nHCM would weaken Braveheart’s differentiation, especially given geographic translation risk from Chinese data.

BRVE has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Braveheart Bio Inc. and is not a guaranteed prediction by Public.com or investment advice.

BRVE Analyst Forecast & Price Prediction

Get the latest BRVE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BRVE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Braveheart Bio Inc. (BRVE) Forecast

Analysts have given BRVE a Strong Buy based on their latest research and market trends.

According to 4 analysts, BRVE has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Braveheart Bio Inc. (BRVE)


BRVE Analyst Forecast & Price Prediction

Get the latest BRVE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in BRVE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BRVE stock data and trends